Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Wide series of adenosine kinase inhibitors undergoing evaluation at Abbott

Dec. 10, 1998

Toray discloses new epsilon opioid receptor ligands

Dec. 10, 1998

Phase II trial of diabetic neuropathy Rx commenced by Myelos

Dec. 10, 1998

Candidate antidepressants available for licensing from Berkeley Lab

Dec. 9, 1998

Lilly obtains exclusive worldwide rights to (R)-fluoxetine

Dec. 9, 1998

First report of efficacy of oral, sustained-release fampridine in SCI

Dec. 9, 1998

Adenosine kinase inhibitors and methods of use described by Abbott

Dec. 8, 1998

Central muscarinic receptor agonists patented by U. of Toledo

Dec. 7, 1998

Zomig copromoted by Cephalon in the U.K.

Dec. 4, 1998

Heterocyclic melatonergic agents designed at ADIR

Dec. 4, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...